{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:25:37Z","timestamp":1785803137890,"version":"3.56.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81925035"],"award-info":[{"award-number":["81925035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673382"],"award-info":[{"award-number":["81673382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00400","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T08:00:20Z","timestamp":1591171220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Bin","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuanbing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting.","volume":"62","author":"Ahmad","year":"2019","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML.","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/IJN.S191837","article-title":"Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment.","volume":"14","author":"Alp","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/bs.acr.2017.11.003","article-title":"Chapter five \u2013 recent advances in nanoparticle-based cancer drug and gene delivery.","volume":"137","author":"Amreddy","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"B5","author":"Bach","year":"2020","journal-title":"Cancer Drug Costs for A Month of Treatment at Initial Food and Drug Administration Approval."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.2174\/0929867325666171229141156","article-title":"Inorganic nanoparticles for cancer therapy: a transition from lab to clinic.","volume":"25","author":"Bayda","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","article-title":"Cancer active targeting by nanoparticles: a comprehensive review of literature.","volume":"141","author":"Bazak","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biom9020060","article-title":"The ROMP: a powerful approach to synthesize novel pH-sensitive nanoparticles for tumor therapy.","volume":"9","author":"Bertrand","year":"2019","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1248\/cpb.c17-00068","article-title":"Endogenous stimuli-responsive nanocarriers for drug delivery.","volume":"45","author":"Chen","year":"2016","journal-title":"Chem. Lett."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1039\/c6cs00592f","article-title":"Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.","volume":"46","author":"Dai","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control Release"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1021\/bm501338r","article-title":"Vorinostat-polymer conjugate nanoparticles for Acid-responsive delivery and passive tumor targeting.","volume":"15","author":"Denis","year":"2014","journal-title":"Biomacromolecules"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs.","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery.","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"B15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/acs.bioconjchem.6b00736","article-title":"Enzyme-responsive liposomes for the delivery of anticancer drugs.","volume":"28","author":"Fouladi","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1021\/nn2033105","article-title":"Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.","volume":"5","author":"Gao","year":"2011","journal-title":"ACS Nano"},{"key":"B17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1148\/radiol.2018181445","article-title":"Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results from a phase I trial.","volume":"291","author":"Gray","year":"2019","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.2147\/IJN.S118727","article-title":"A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.","volume":"11","author":"Han","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1016\/j.ejmech.2009.06.036","article-title":"Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells.","volume":"44","author":"Ishii","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35734","DOI":"10.1021\/acsami.8b10901","article-title":"Cancer chemoradiotherapy duo: nano-enabled targeting of DNA lesion formation and DNA damage response.","volume":"10","author":"Jiang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/acs.molpharmaceut.8b01065","article-title":"Targeted lipid nanoemulsions encapsulating epigenetic drugs exhibit selective cytotoxicity on CDH1(-)\/FOXM1(+) triple negative breast cancer cells.","volume":"16","author":"Kim","year":"2019","journal-title":"Mol. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1021\/acs.biomac.8b00221","article-title":"Histone deacetylase inhibitor (HDACi) conjugated polycaprolactone for combination cancer therapy.","volume":"19","author":"Kularatne","year":"2018","journal-title":"Biomacromolecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1208\/s12249-017-0863-5","article-title":"Co-delivery of vorinostat and etoposide via disulfide cross-linked biodegradable polymeric nanogels: synthesis, characterization, biodegradation, and anticancer activity.","volume":"19","author":"Kumar","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0122-4","article-title":"Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.","volume":"13","author":"Kwak","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"B26","first-page":"3807","article-title":"Artemisinin-transferrin conjugate retards growth of breast tumors in the rat.","volume":"29","author":"Lai","year":"2009","journal-title":"Anticancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1039\/c9bm00895k","article-title":"Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma.","volume":"7","author":"Lee","year":"2019","journal-title":"Biomater. Sci."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033860","article-title":"Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts.","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy.","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy.","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1016\/j.biomaterials.2012.05.035","article-title":"TAT-modified nanosilver for combating multidrug-resistant cancer.","volume":"33","author":"Liu","year":"2012","journal-title":"Biomaterials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1470-2045(18)30332-2","article-title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1021\/nn405674m","article-title":"Nanoparticles for combination drug therapy.","volume":"7","author":"Ma","year":"2013","journal-title":"ACS Nano"},{"key":"B34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.","volume":"164","author":"Maeda","year":"2012","journal-title":"J. Control Release"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/IJN.S24582","article-title":"Nanoinformatics: a new area of research in nanomedicine.","volume":"7","author":"Maojo","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.nano.2013.05.017","article-title":"Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.","volume":"9","author":"Martin","year":"2013","journal-title":"Nanomedicine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.2174\/0929867324666170830113755","article-title":"The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes.","volume":"25","author":"Palazzolo","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects.","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1021\/acs.nanolett.7b03756","article-title":"Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib\/vorinostat.","volume":"17","author":"Peng","year":"2017","journal-title":"Nano Lett."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1527","article-title":"Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy.","volume":"11","author":"Qiao","year":"2019","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"14925","DOI":"10.18632\/oncotarget.14742","article-title":"Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy.","volume":"8","author":"Ruttala","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.trecan.2018.04.002","article-title":"Nanoinformatics revolutionizes personalized cancer therapy.","volume":"4","author":"Sadan","year":"2018","journal-title":"Trends Cancer"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia.","volume":"11","author":"San Jose-Eneriz","year":"2019","journal-title":"Cancers"},{"key":"B44","first-page":"50","article-title":"How does P-glycoprotein recognize its substrates?","volume":"36","author":"Seelig","year":"1998","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours.","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2147\/IJN.S125300","article-title":"Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.","volume":"12","author":"Singleton","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi.","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-16-2433","article-title":"Phase III heat study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions.","volume":"24","author":"Tak","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.biomaterials.2015.02.015","article-title":"Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.","volume":"51","author":"Wang","year":"2015","journal-title":"Biomaterials"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020148","article-title":"Histone deacetylase inhibitors and phenotypical transformation of cancer cells.","volume":"11","author":"Wawruszak","year":"2019","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081191","article-title":"Reactive oxygen species in the tumor microenvironment: an overview.","volume":"11","author":"Weinberg","year":"2019","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours.","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1021\/mp200597r","article-title":"Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy.","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.2147\/IJN.S136142","article-title":"Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.","volume":"12","author":"Yuan","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"B55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1039\/c9cc09019c","article-title":"Peptide-templated gold nanoparticle nanosensor for simultaneous detection of multiple posttranslational modification enzymes.","volume":"56","author":"Zhang","year":"2019","journal-title":"Chem. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.20892\/j.issn.2095-3941.2017.0054","article-title":"Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.","volume":"14","author":"Zhang","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1039\/c7sc04853j","article-title":"Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy.","volume":"9","author":"Zhao","year":"","journal-title":"Chem. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cbic.201800201","article-title":"Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery.","volume":"19","author":"Zhao","year":"","journal-title":"Chembiochem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/open.201402141","article-title":"Design and evaluation of tumor-specific dendrimer epigenetic therapeutics.","volume":"4","author":"Zong","year":"2015","journal-title":"ChemistryOpen"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T08:00:30Z","timestamp":1591171230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":59,"alternative-id":["10.3389\/fcell.2020.00400"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00400","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"400"}}